Literature DB >> 8774180

Changes in cartilage proteoglycan aggrecan after intra-articular injection of interleukin-1 in rabbits: studies of synovial fluid and articular cartilage.

C Lundberg1, I Asberg, M Ionescu, A Reiner, G Smedegård, A R Poole.   

Abstract

OBJECTIVE: To determine how acute but transient inflammation affects the cartilage proteoglycan aggrecan and the value of analyses of synovial fluid to study this.
METHODS: For 96 hours after a single intra-articular injection of rabbit knees with human interleukin-1 alpha (IL-1 alpha) or vehicle, articular cartilage and synovial fluid were examined using a putative indicator of aggrecan synthesis (aggrecan chondroitin sulphate epitope 846), immunoreactive keratan sulphate, and total glycosaminoglycan (GAG) content. Aggrecan extractability (with 0.5 M NaCl) followed by 4 M guanidine hydrochloride extraction permitted analyses of cartilage damage, total content and aggrecan heterogeneity. Aggrecan epitopes as well as GAG were assayed in synovial fluid. Changes were related to total joint leucocyte content in synovial fluid.
RESULTS: At 10 ng, IL-1 alpha produced a transient increase in synovial fluid leucocytes at six hours and 24 hours. This accompanied a reduction in content and increased extractability of GAG, which was greatest in the tibial medial compartment of the knee. Further studies of this compartment showed no change in keratan sulphate epitope content, but a transient increase in extractability in 0.5 M NaCl. Epitope 846 content and extractability were unchanged. Total contents and extractability for GAG were inversely correlated in both controls and joints injected with IL-1 alpha. These changes were accompanied by transient increases in GAG, keratan sulphate epitope, and 846 content in synovial fluid.
CONCLUSION: According to the aggrecan component measured, damage to the matrix of articular cartilage was sometimes reflected by a transient increased extractability and a net loss of aggrecan. There was always an increased release of GAG, and keratan sulphate, and 846 epitopes into synovial fluid. These studies show that changes in aggrecan epitopes and GAG in synovial fluid reflect changes in cartilage metabolism induced by acute transient inflammation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774180      PMCID: PMC1010232          DOI: 10.1136/ard.55.8.525

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  34 in total

1.  Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin 1 antibodies in experimental arthritis.

Authors:  F A van de Loo; O J Arntz; I G Otterness; W B van den Berg
Journal:  J Rheumatol       Date:  1992-03       Impact factor: 4.666

2.  N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage.

Authors:  P Loulakis; A Shrikhande; G Davis; C A Maniglia
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

3.  Immunochemical markers of joint inflammation, skeletal damage and repair: where are we now?

Authors:  A R Poole
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

4.  Intra-articular administration of interleukin-1 causes prolonged suppression of cartilage proteoglycan synthesis in rats.

Authors:  S Chandrasekhar; A K Harvey; P S Hrubey
Journal:  Matrix       Date:  1992-02

5.  The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain.

Authors:  J D Sandy; C R Flannery; P J Neame; L S Lohmander
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

6.  In vivo effects of interleukin-1 on articular cartilage. Prolongation of proteoglycan metabolic disturbances in old mice.

Authors:  H M van Beuningen; O J Arntz; W B van den Berg
Journal:  Arthritis Rheum       Date:  1991-05

7.  Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease.

Authors:  G Rizkalla; A Reiner; E Bogoch; A R Poole
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

8.  Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions.

Authors:  T Saxne; D Heinegård
Journal:  Arthritis Rheum       Date:  1992-04

9.  Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan. Human-specific repeats, and additional alternatively spliced forms.

Authors:  K J Doege; M Sasaki; T Kimura; Y Yamada
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

10.  Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis.

Authors:  A R Poole; M Ionescu; A Swan; P A Dieppe
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

View more
  2 in total

1.  Neural EGFL like 1 as a potential pro-chondrogenic, anti-inflammatory dual-functional disease-modifying osteoarthritis drug.

Authors:  Chenshuang Li; Zhong Zheng; Pin Ha; Wenlu Jiang; Emily A Berthiaume; Seungjun Lee; Zane Mills; Hsinchuan Pan; Eric C Chen; Jie Jiang; Cymbeline T Culiat; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Biomaterials       Date:  2019-10-12       Impact factor: 12.479

2.  Select Biomarkers on the Day of Anterior Cruciate Ligament Reconstruction Predict Poor Patient-Reported Outcomes at 2-Year Follow-Up: A Pilot Study.

Authors:  Christian Lattermann; Caitlin E-W Conley; Darren L Johnson; Emily K Reinke; Laura J Huston; Janet L Huebner; Ching-Heng Chou; Virginia B Kraus; Kurt P Spindler; Cale A Jacobs
Journal:  Biomed Res Int       Date:  2018-07-19       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.